Join us for an exclusive AI-powered pathology event by the Boston Harbor.
Enjoy insightful discussions, handcrafted cocktails, and gourmet bites while connecting with our team and industry leaders. Get an exclusive look at AISight® and our latest AI-driven pathology tools in a stunning waterfront setting. Don’t miss this premier networking experience—reserve your spot today!
Join us at USCAP 2025 as we showcase the next wave of AI-powered pathology. Visit our booth for live demos, attend our scientific programming, and network with industry leaders at our exclusive H&E by the Sea party.
Be part of the Tides of Transformation—where pathology meets the future.
March 22 - 27, 2025
Boston Convention Center
Booth 412
Meet AISight®
PathAI Scientific Program
Oral Presentations
Evaluation of an AI-powered digital pathology tool for automated tumor detection and case prioritization
Clinical Utility of Tumor-Detect AI Algorithm for Detection of Prostate Cancer on Transurethral Resection Specimens
Poster 155,March 25th, 1:00 PM - 4:30 PM View in Program Partner: The Ohio State University Wexner Medical Center
Machine Learning-Enabled Pathological Features of Post-preoperative Therapy Surgical Specimens Improves Recurrence Prediction in Patients with Triple Negative Breast Cancer (TNBC) Treated with Neoadjuvant Chemotherapy (NAC)
Poster 31,March 26th, 1:00 PM - 4:30 PM View in Program Partner Presentation: Dana Farber Cancer Institute
AI-Powered Automated Quality Control of Whole Slide Images by Artifact Detect Tool
Poster 250,March 26th, 9:30 AM - 12:00 PM View in Program Partner: The Ohio State University Wexner Medical Center
Optimize Operational Efficiency
Automates workflows, flags urgent cases, and streamlines critical tasks, reducing technician and pathologist manual effort and allowing labs to manage case volumes efficiently.
Enhance Collaboration
Enables interdisciplinary communication and teamwork with real-time consultation tools such as AISight Live, improving collaboration on complex cases.
AI-Native IMS
With direct platform integration of AI algorithms enabling next-generation workflow efficiency such as case prioritization, automated case assignment and artifact management.
Versatile Functionality
Supports a wide range of use cases—including workflow optimization, histopathology research, education, and training—streamlining workflows and eliminating the need for multiple systems.
AIM TUMOR CELLULARITY: Automate detection of tumor hotspots and conduct tumor sufficiency assessments for molecular testing with single-cell resolution
ARTIFACT DETECT: Automated detection of artifact by action-oriented classes (Scanning, Cover slipping, Sectioning, Grossing and Other) to monitor quality
TUMOR DETECT: Automated detection of tumor across all common carcinomas for case prioritization and case triaging
AIM IHC BREAST PANEL: Automated scoring of major Breast Cancer biomarkers (HER2, ER, PR, Ki67) following ASCO/CAP guidelines
MET PREDICT: AI-powered insights on molecular alteration status of specimen, based on H&E images, enhancing the molecular testing prioritization
PATH ASSIST DERM: AI-powered tool designed to streamline dermatopathology workflows by automating triaging, specimen orientation and lesion measurement.
AIM MASH: Automated MASH CRN Scoring along with representation of hepatocellular ballooning, fibrosis, lobular inflammation, portal inflammation, and interface hepatitis
AIM PDL1: Automated scoring of PD-L1 positivity in tumor and immune cells for NSCLC, Urothelial Carcinoma, HNSCC, and Melanoma
AIM-HI Ulcerative Colitis: Coming soon, Automated Geboes Scoring for inflammation severity within cases with known ulcerative colitis
AI NATIVE SUITE
Algorithms for Pathology Research
AISight further comes with PathAI’s large menu of state-of-the-art RUO algorithms across research, workflow optimization, assisted scoring, and biomarker quantification, and assistants use cases embedded directly into the IMS.
CASE STUDY
AI-Assisted Titer Selection in Early Assay Development
PathAI deployed IHC Explore on prostate cancer specimens stained with a novel, in-development assay
IHC Explore quantifies staining intensity at single-cell resolution, enabling rapid assay characterization and titer optimization
Continuous staining intensity measurement provides added value for next-generation biomarkers and precision medicine strategies
Schedule a free demo at USCAP 2025 today
Fuel your pathology workflows & research with AISight®
AISight is for Research Use Only in the US; AISight Dx is CE-IVD marked in Europe, UK and Switzerland. Tumor Detect, Artifact Detect, are workflows on AISight®. AIM-Tumor Cellularity, AIM-MASH, AIM IHC Breast Panel, MET Predict, PathAssist Derm, AIM-HI UC, AIM PDL1 are for research use only. Not for use in diagnostic procedures.
.png)
-1.png?width=2000&height=1322&name=Untitled%20design%20(4)-1.png "PathAI USCAP")
-1.png?width=1200&length=1200&name=DONE%20AISIght%20Brochure%20(6)-1.png)
-1.png?width=1200&length=1200&name=DONE%20AISIght%20Brochure%20(3)-1.png)
-1.png?width=1200&length=1200&name=DONE%20AISIght%20Brochure%20(5)-1.png)
-1.png?width=1200&length=1200&name=DONE%20AISIght%20Brochure%20(7)-1.png)
.png?width=1200&length=1200&name=DONE%20AISIght%20Brochure%20(8).png)
-1.png?width=1200&length=1200&name=DONE%20AISIght%20Brochure%20(1)-1.png)
-1.png?width=1200&length=1200&name=DONE%20AISIght%20Brochure%20(2)-1.png)
-1.png?width=1200&length=1200&name=DONE%20AISIght%20Brochure%20(4)-1.png)
